Fig. 1From: Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumabClinical course of disease and time-points of collected tumor biopsies. On the right: chronological schema of disease appearance and treatments, on years. On the left: time of sample collection (red dots) on days respect to initiation to atezolizumab first exposure. CMF: cyclophosphamide, methotrexate and fluorouracil; Biopsy Dx: diagnostic biopsy; LAD: lymphadenopathyBack to article page